Haemonetics (HAE) Expected to Announce Earnings on Thursday

Key Points

• Haemonetics is set to release its Q1 2026 earnings on August 7th, with analysts predicting earnings of $1.02 per share and revenue of $305.12 million.
• The company's last quarterly earnings beat estimates, reporting $1.24 earnings per share and $330.60 million in revenue, despite a 3.5% decline year-over-year.
• Haemonetics is currently rated as a "Moderate Buy" by analysts with an average price target of $97.30.

Haemonetics (NYSE:HAE - Get Free Report) will likely be announcing its Q1 2026 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $1.02 per share and revenue of $305.12 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.700-5.000 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The company's revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business posted $0.90 earnings per share. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Price Performance

Shares of NYSE HAE traded up $0.84 during mid-day trading on Monday, hitting $75.61. 125,052 shares of the stock were exchanged, compared to its average volume of 734,490. The company has a market cap of $3.63 billion, a P/E ratio of 22.86, a PEG ratio of 1.21 and a beta of 0.40. The stock's fifty day simple moving average is $72.88 and its two-hundred day simple moving average is $67.57. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62. Haemonetics has a twelve month low of $55.30 and a twelve month high of $94.99.

Analyst Ratings Changes

Several analysts have recently weighed in on HAE shares. Raymond James Financial reaffirmed a "strong-buy" rating and set a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Needham & Company LLC dropped their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective for the company in a report on Wednesday, July 9th. Robert W. Baird initiated coverage on shares of Haemonetics in a report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price objective for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $100.00 price target on shares of Haemonetics in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $97.30.

Institutional Investors Weigh In On Haemonetics

Several institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock valued at $9,923,000 after acquiring an additional 9,051 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock valued at $1,877,000 after acquiring an additional 971 shares in the last quarter. Empowered Funds LLC lifted its position in Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 372 shares in the last quarter. Caxton Associates LLP bought a new stake in Haemonetics in the 1st quarter valued at $216,000. Finally, United Services Automobile Association bought a new stake in Haemonetics in the 1st quarter valued at $212,000. 99.67% of the stock is owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.